Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
I-DROP MGD
- Development stage
- Unknown
- Lead developer
- I-MED Pharma
- Administration
- Ophthalmic
01
Overview
I-DROP MGD is a preservative-free, viscoadaptive artificial tear developed by I-MED Pharma specifically for the management of evaporative dry eye disease, particularly that associated with Meibomian Gland Dysfunction (MGD). The formulation features a high-molecular-weight sodium hyaluronate (0.20%) combined with a lipid-layer enhancer. This combination is designed to stabilize the tear film, reduce evaporation, and provide long-lasting ocular surface lubrication. Unlike standard artificial tears, its viscoadaptive properties allow the drop to remain on the eye longer, providing symptomatic relief for moderate to severe dry eye symptoms by mimicking the natural tear film's lipid layer.
- Brand names
- I-DROP MGD
Beyond the preview
Go deeper on I-DROP MGD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on I-DROP MGD.